14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.
James Black Foundation
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.
Bristol-Myers Squibb
Side chain cyclization based on serine residues: synthesis, structure, and activity of a novel cyclic analogue of the parathyroid hormone fragment 1-11.
University of Padova
Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe.
Pharmaceutical Research Institute
Lead optimization of pyrido[2,3-d][1]benzazepin-6-one derivatives leading to the discovery of a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) antagonist (DS69910557).
Daiichi Sankyo
Discovery of novel, potent, and orally bioavailable pyrido[2,3-d][1]benzazepin-6-one antagonists for parathyroid hormone receptor 1.
Daiichi Sankyo
Discovery of novel PTHR1 antagonists: Design, synthesis, and structure activity relationships.
Daiichi Sankyo
New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.
Astrazeneca
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Bristol-Myers Squibb
Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist.
Chugai Pharmaceutical
Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism.
Chugai Pharmaceutical
Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with BroadĪ² Residue Distribution.
University of Wisconsin-Madison
